Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

232.36 +0.07 (+0.03%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
82 83 Next >
News headline image
The 7 Best Momentum Stocks You Can Purchase Today ↗
If you’re looking for hot opportunities in the market, here are just a few of the best momentum stocks to buy today. 
Via InvestorPlace
News headline image
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks? ↗
These incredible businesses have long histories of successes behind them, and more to come. 
Via The Motley Fool
News headline image
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy ↗
The drugmaker is handling its biggest obstacle yet relatively well. 
Via The Motley Fool
News headline image
Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Freeport-McMoRan Inc. (NYSE: FCX) could go higher by a "couple of points, once the Chinese start manipulating their market higher, but that’s all... 
Via Benzinga
News headline image
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying? ↗
Letting your winners run is a proven way to generate extraordinary portfolio returns without cutting them off by taking profits. 
Via InvestorPlace
News headline image
AbbVie Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
2 Magnificent Dividend Growth Stocks to Load Up On Right Now ↗
These two dividend-growth stocks are fantastic buys. 
Via The Motley Fool
News headline image
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
News headline image
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 ↗
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
Via InvestorPlace
News headline image
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
News headline image
7 Dividend Stocks Worth Holding for the Long Haul ↗
These dividend stocks are worth holding for the long term both for upside and income production that can add up quickly. 
Via InvestorPlace
News headline image
AbbVie Analysts Boost Their Forecasts Following Strong Earnings ↗
AbbVie Inc (NYSE: ABBV) reported better-than-expected fourth-quarter earnings on Friday. 
Via Benzinga
News headline image
AbbVie Earnings Preview ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On AbbVie ↗
 
Via Benzinga
News headline image
Why AbbVie Stock Flew Higher on Monday ↗
Investors and pundits alike continued to be impressed by the company's latest earnings report. 
Via The Motley Fool
News headline image
Drug Maker AbbVie Stock Sees RS Rating Jump To 81 ↗
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
News headline image
Better Dividend Stock: Pfizer vs. AbbVie ↗
Both offer above-average yields but which can deliver the most dividend income over the long run? 
Via The Motley Fool
News headline image
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
3 Fabulous Dividend Stocks to Buy in February ↗
These stocks offer great dividends and more. 
Via The Motley Fool
News headline image
7 Dividend Stocks That Pay Me More Than $500 Per Month ↗
These stocks pay safe, reliable, and growing dividends. 
Via The Motley Fool
News headline image
AbbVie (ABBV) Q4 2023 Earnings Call Transcript ↗
ABBV earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall ↗
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. 
Via Benzinga
News headline image
AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira. ↗
The company raised its long-term guidance for four products on Friday. Two will top $27 billion in 2027 sales, the company says. 
Via Investor's Business Daily
News headline image
AbbVie Posts Less-Than-Healthy Financial Results For 2023 ↗
Pharmaceuticals company AbbVie reported its Q4 and full year financial results for 2023. 
Via Talk Markets
News headline image
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
News headline image
Earnings Scheduled For February 2, 2024 ↗
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024 ↗
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out. 
Via InvestorPlace
Topics Economy
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.